HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].

AbstractBACKGROUND:
Subacute cutaneous lupus erythematosus is an uncommon dermatosis characterised by a non-scarring, annular photo-distributed dermatosis associated with anti-Ro/SSA antibodies. It is remarkable as a paraneoplastic syndrome (12 cases in the literature). We report two cases of subacute cutaneous lupus erythematosus occurring in patients treated for metastatic breast adenocarcinoma.
CASE REPORTS:
Case 1: a 72-year-old woman with breast carcinoma relapsing after surgery, chemotherapy, hormone therapy, and without treatment for 6 months, was admitted for an acute erythematous slightly squamous and photo-distributed eruption. On clinical examination, she was found to be presenting polyadenopathy and pleural effusion. Case 2: a 46-year-old woman with a history of breast carcinoma was admitted for an erythematopapular, annular and photo-distributed eruption occurring after a second breast cancer relapse and five months after initiation of docetaxel. A new line of chemotherapy initially resulted in regression of the lesions, and progression of the breast cancer was associated with cutaneous relapse.
DISCUSSION:
The diagnosis of subacute cutaneous lupus erythematosus was supported in our two patients by the presence of an annular photo-distributed eruption associated with positive testing for anti-Ro/SSA antibodies. Occurrence of the eruption in both cases with relapse of the neoplasia and its improvement after oncological treatment reinforced the diagnosis of paraneoplastic syndrome in one case, and the use of chemotherapy known to trigger lupus could have suggested a diagnosis of drug-induced subacute cutaneous lupus erythematosus. Thus, the association between lupus and cancer is relevant.
AuthorsA Gantzer, S Regnier, A Cosnes, N Ortonne, P Wolkenstein, M Bagot, T-A Duong
JournalAnnales de dermatologie et de venereologie (Ann Dermatol Venereol) Vol. 138 Issue 5 Pg. 409-17 (May 2011) ISSN: 0151-9638 [Print] France
Vernacular TitleLupus cutané subaigu et cancer: deux cas et revue de la littérature.
PMID21570567 (Publication Type: Case Reports, Journal Article, Review)
CopyrightCopyright © 2011 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Antibodies, Antinuclear
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Hormonal
  • Autoantigens
  • Ribonucleoproteins
  • SS-A antibodies
  • SS-A antigen
  • Taxoids
  • Tamoxifen
  • Docetaxel
  • Bevacizumab
  • Epirubicin
  • Cyclophosphamide
  • Trastuzumab
  • Paclitaxel
  • Fluorouracil
Topics
  • Adenocarcinoma (complications, drug therapy, radiotherapy, surgery)
  • Aged
  • Antibodies, Antinuclear (blood)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Autoantigens (immunology)
  • Bevacizumab
  • Breast Neoplasms (complications, drug therapy, radiotherapy, surgery)
  • Combined Modality Therapy
  • Cyclophosphamide (administration & dosage)
  • Docetaxel
  • Epirubicin (administration & dosage)
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Lupus Erythematosus, Cutaneous (chemically induced, diagnosis, etiology, immunology)
  • Mastectomy (methods)
  • Middle Aged
  • Paclitaxel (administration & dosage)
  • Paraneoplastic Syndromes (chemically induced, diagnosis, etiology, immunology)
  • Ribonucleoproteins (immunology)
  • Salvage Therapy
  • Tamoxifen (therapeutic use)
  • Taxoids (administration & dosage, adverse effects)
  • Trastuzumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: